Citations

Showing 10 of 108094 citations.

Aortic valve hemodynamics in atrial fibrillation: Should the highest Doppler signal be used to estimate severity of aortic stenosis?
Alsidawi, Said , Khan, Sana , Pislaru, Sorin V. , Sabbah, Michael S. , Nkomo, Vuyisile T. , Alsidawi, Said

Mayo Clinic

Echocardiography | May 14, 2018 | Volume: 35 | Issue: 6 | Pages: 869-871

10.1111/echo.14020 | PMID 29756640 Get It

Grading severity of AS in AF is complicated by varying stroke volumes associated with fluctuating maximum velocities and pressure gradients across the aortic valve. Current guidelines recommend averaging five continuous‐wave peak velocity and mean gradient (MG) Doppler signals across the aortic valve when estimating severity of AS in AF. However, it is unknown when grading severity of AS how the average of multiple Doppler signals vs the highest Doppler signal in AF compares to the Doppler signals when the patient is in normal sinus rhythm. We present a series of patients with AS who had two echocardiograms performed within 2‐4 months of each other, one when in normal sinus rhythm and one when in AF, and compare the aortic valve hemodynamics associated with the two rhythms.
Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
Karnes, R. Jeffrey , Sharma, Vidit , Choeurng, Voleak, Ashab, Hussam Al-Deen, Erho, Nicholas , Alshalalfa, Mohammed , Ross, Ashley E. , Yousefi, Kasra, Tsai, Harrison , Zhao, Shuang G. , Tosoian, Jeffrey J. , Haddad, Zaid , Takhar, Mandeep, Chang, S. Laura , Spratt, Daniel E. , Jenkins, Robert B. , Klein, Eric A. , Nguyen, Paul L. , Dicker, Adam P. , Feng, Felix Y. , Schaeffer, Edward M. , Spratt, Daniel E , Klein, Eric A , Trock, Bruce J , Zhao, Shuang G , Abdollah, Firas , Den, Robert B. , Davicioni, Elai , Lotan, Tamara Levin , Dicker, Adam P

Mayo Clinic

Clinical Cancer Research | May 14, 2018 | Volume: 24 | Issue: 16 | Pages: 3908-3916

10.1158/1078-0432.ccr-17-2745 | PMID 29760221 Get It

Abstract Purpose: Currently, no genomic signature exists to distinguish men most likely to progress on adjuvant androgen deprivation therapy (ADT) after radical prostatectomy for high-risk prostate cancer. Here we develop and validate a gene expression signature to predict response to postoperative ADT. Experimental Design: A training set consisting of 284 radical prostatectomy patients was established after 1:1 propensity score matching metastasis between adjuvant-ADT (a-ADT)-treated and no ADT–treated groups. An ADT Response Signature (ADT-RS) was identified from neuroendocrine and AR signaling–related genes. Two independent cohorts were used to form three separate data sets for validation (set I, n = 232; set II, n = 435; set III, n = 612). The primary endpoint of the analysis was postoperative metastasis. Results: Increases in ADT-RS score were associated with a reduction in risk of metastasis only in a-ADT patients. On multivariable analysis, ADT-RS by ADT treatment interaction term remained associated with metastasis in both validation sets (set I: HR = 0.18, Pinteraction = 0.009; set II: HR = 0.25, Pinteraction = 0.019). In a matched validation set III, patients with Low ADT-RS scores had similar 10-year metastasis rates in the a-ADT and no-ADT groups (30.1% vs. 31.0%, P = 0.989). Among High ADT-RS patients, 10-year metastasis rates were significantly lower for a-ADT versus no-ADT patients (9.4% vs. 29.2%, P = 0.021). The marginal ADT-RS by ADT interaction remained significant in the matched dataset (Pinteraction = 0.035). Conclusions: Patients with High ADT-RS benefited from a-ADT. In combination with prognostic risk factors, use of ADT-RS may thus allow for identification of ADT-responsive tumors that may benefit most from early androgen blockade after radical prostatectomy. We discovered a gene signature that when present in primary prostate tumors may be useful to predict patients who may respond to early ADT after surgery. Clin Cancer Res; 24(16); 3908–16. ©2018 AACR.
Every physician should discourage cigarette smoking
Brott, Thomas G. , Meschia, James F.

Mayo Clinic

European Journal of Neurology | May 14, 2018 | Volume: 25 | Issue: 6 | Pages: No page available

10.1111/ene.13626 | PMID 29756320 Get It

Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder
Li, Jiao , Ruskey, Jennifer A. , Arnulf, Isabelle , Dauvilliers, Yves , Hu, Michele T.M., Högl, Birgit , Leblond, Claire S. , Ambalavanan, Amirthagowri , Ross, Jay P. , Bourassa, Cynthia V., Spiegelman, Dan , Laurent, Sandra B., Stefani, Ambra , Monaca, Christelle, Boivin, Michel , Antelmi, Elena , Young, Peter, Heidbreder, Anna , Ferman, Tanis J. , Dion, Patrick A. , Désautels, Alex , Gagnon, Jean‐François, Dupré, Nicolas , Montplaisir, Jacques , Boeve, Bradley F., Ross, Owen A. , Shulman, Joshua , Labbé, Catherine, Antelmi, Elena , Ross, Owen A , Dauvilliers, Yves , Ferman, Tanis J , Stefani, Ambra , Zhou, Sirui , Cochen De Cock, Valérie , Ferini-Strambi, Luigi , Plazzi, Giuseppe , Labbé, Catherine , Fan, Dongsheng , Fon, Edward A , Boeve, Bradley F. , Postuma, Ronald B. , Rouleau, Guy Armand , Gan‐Or, Ziv , Arnulf, Isabelle , Hu, Michele T M , Högl, Birgit , Heidbreder, Anna

Mayo Clinic

Movement Disorders | May 14, 2018 | Volume: 33 | Issue: 6 | Pages: 1016-1020

10.1002/mds.27385 | PMID 29756641 Get It

ABSTRACT Background: MAPT haplotypes are associated with PD, but their association with rapid eye movement sleep behavior disorder is unclear. Objective: To study the role of MAPT variants in rapid eye movement sleep behavior disorder. Methods: Two cohorts were included: (A) PD (n = 600), rapid eye movement sleep behavior disorder (n = 613) patients, and controls (n = 981); (B) dementia with Lewy bodies patients with rapid eye movement sleep behavior disorder (n = 271) and controls (n = 950). MAPT ‐associated variants and the entire coding sequence of MAPT were analyzed. Age‐, sex‐, and ethnicity‐adjusted analyses were performed to examine the association between MAPT , PD, and rapid eye movement sleep behavior disorder. Results: MAPT‐ H2 variants were associated with PD (odds ratios: 0.62‐0.65; P = 0.010‐0.019), but not with rapid eye movement sleep behavior disorder. In PD, the H1 haplotype odds ratio was 1.60 (95% confidence interval: 1.12‐2.28; P = 0.009), and the H2 odds ratio was 0.68 (95% confidence interval: 0.48‐0.96; P = 0.03). The H2/H1 haplotypes were not associated with rapid eye movement sleep behavior disorder. Conclusions: Our results confirm the protective effect of the MAPT ‐H2 haplotype in PD, and define its components. Furthermore, our results suggest that MAPT does not play a major role in rapid eye movement sleep behavior disorder, emphasizing different genetic background than in PD in this locus. © 2018 International Parkinson and Movement Disorder Society
In Vitro and In Vivo Correlation of Bone Morphogenetic Protein-2 Release Profiles from Complex Delivery Vehicles
Olthof, Maurits G.L. , Tryfonidou, Marianna A. , Dadsetan, Mahrokh, Dhert, Wouter J.A. , Yaszemski, Michael J. , Lu, Lichun , Kempen, Diederik H.R.

Mayo Clinic

Tissue Engineering Part C: Methods | May 14, 2018 | Volume: 24 | Issue: 7 | Pages: 379-390

10.1089/ten.tec.2018.0024 | PMID 29756545 Get It

Esthesioneuroblastoma with distant metastases: Systematic review & meta‐analysis
Marinelli, John P. , Janus, Jeffrey R. , Link, Michael J., Foote, Robert L. , Lohse, Christine M. , Price, Katharine A. , Chintakuntlawar, Ashish V. , Chintakuntlawar, Ashish V , Gompel, Jamie J. Van

Mayo Clinic

Head & Neck | May 14, 2018 | Volume: 40 | Issue: 10 | Pages: 2295-2303

10.1002/hed.25209 | PMID 29756250 Get It

AbstractBackgroundThe purpose of this study was to determine the clinical outcomes and review the management strategies for metastatic esthesioneuroblastoma.MethodsWe conducted a systematic review and meta‐analysis.ResultsForty‐eight studies totaling 118 patients met inclusion criteria. Chemotherapy in combination with surgery and/or radiation exhibited the best overall survival when compared to monotherapy and no treatment (P < .001). However, most patients (66%) received either monotherapy or no therapy. The number and location of metastases among the 3 treatment groups did not significantly differ (P = .85). Treatment modality remained significantly associated with overall survival on multivariable analysis (P < .001). Platinum‐based chemotherapy was most commonly utilized but did not provide a survival benefit when compared with all other regimens (P = .88).ConclusionDistant metastases with esthesioneuroblastoma portend a poor prognosis. Chemotherapy in combination with surgery and/or radiation was associated with improved overall survival. Further research into the optimal systemic therapeutic regimen for patients with distant metastases is critical.
Ewing sarcoma of the head and neck: The Mayo Clinic experience
Olson, Michael D. , Abel, Kathryn M. Van , Wehrs, Rebecca N., García, Joaquín J., Moore, Eric J. , Van Abel, Kathryn M

Mayo Clinic

Head & Neck | May 14, 2018 | Volume: 40 | Issue: 9 | Pages: 1999-2006

10.1002/hed.25191 | PMID 29756246 Get It

AbstractBackgroundTreatment options of Ewing sarcoma of the head and neck include surgery, radiotherapy (RT), and chemoradiotherapy. However, local control can be challenging.MethodsWe conducted a retrospective review of all patients with head and neck Ewing sarcoma treated from 1972 to 2015 at a single tertiary care hospital.ResultsSeventeen patients met criteria (median 21 years, range 5‐58 years; 5 women). Mean follow‐up was 10.4 years (range 2.2‐39 years). Tumors occurred commonly in the cervical spine (5/17), the skull (3/17), and the paranasal sinuses (3/17). A total of 14 of 17 patients underwent surgical resection, 9 with gross total resection. After multimodality therapy, the 5‐year overall survival (OS) and recurrence‐free survival (RFS) was 87% and 75%, respectively.ConclusionCombined multimodal treatment resulted in a 5‐year OS and RFS of 87% and 75%, respectively. Aggressive surgical resection with adjuvant chemoradiotherapy should be considered. Although negative margin surgery is the goal, subtotal resection may be acceptable in the setting of adjuvant treatment.
Reserve-building activities attenuate treatment burden in chronic illness: The mediating role of appraisal and social support
Schwartz, Carolyn E. , Zhang, Jie , Michael, Wesley, Eton, David T. , Rapkin, Bruce D.

Mayo Clinic

Health Psychology Open | May 14, 2018 | Volume: 5 | Issue: 1 | Pages: No page available

10.1177/2055102918773440 | PMID 29785278 Get It

This study examines the importance of four psychosocial factors—personality, cognitive appraisal of quality of life, social support, and current reserve-building—in predicting treatment burden in chronically ill patients. Chronically ill patients ( n = 446) completed web-based measures. Structural equation modeling was used to investigate psychosocial factors predicting treatment burden. Reserve-building activities indirectly reduced treatment burden by: (1) reducing health worries appraisals, (2) reducing financial difficulties, (3) increasing calm and peaceful appraisals, and (4) increasing perceived social support. These findings point to key behaviors that chronically ill people can use to attenuate their treatment burden.
Association of Cardiovascular Health with Epicardial Adipose Tissue and Intima Media Thickness: The Kardiovize Study
Hrusková, J , Maugeri, Andrea , Podroužková, Helena, Štípalová, Tatiana, Jakubík, Juraj , Barchitta, Martina , Medina‐Inojosa, José R. , Homolka, Martin , Agodi, Antonella , Kunzová, Šárka , Sochor, Ondřej , Vinciguerra, Manlio , Vinciguerra, Manlio , Medina-Inojosa, José R , Kunzova, Sarka , López-Jiménez, Francisco

Mayo Clinic

Journal of Clinical Medicine | May 14, 2018 | Volume: 7 | Issue: 5 | Pages: 113

10.3390/jcm7050113 | PMID 29757253 Get It

Background: Intima-media thickness (IMT) has been proposed as a measurement of subclinical atherosclerosis and has been associated with cardiovascular disease (CVD). Epicardial adipose tissue (EAT) is a fat depot between the pericardium and myocardium and has been associated with coronary atherosclerosis. The relationship between IMT and EAT thickness has not been reported before. We investigated the relationship between EAT thickness, IMT, CVD risk factors, and ideal cardiovascular health (CVH) metrics using subjects from the Kardiovize Brno 2030 cohort study, a random urban sample population in Central Europe. Methods: We studied 102 individuals (65 males) aged 25–64 years (median = 37 years) with no current or past CVD history. We measured IMT using a vascular ultrasound and EAT thickness using transthoracic echocardiography, and collected data on anthropometric factors, CVD risk factors, and CVH score. Correlation tests and multiple linear regression models were applied. Results: In the age- and gender-adjusted model, we demonstrated that, among CVD risk factors, only BMI was significantly and positively associated with EAT thickness (β = 0.182, SE = 0.082, p = 0.030), while no significant associations with IMT were evident. Although both EAT thickness and IMT were negatively correlated with CVH score (r = −0.45, p < 0.001, and r = −0.38, p < 0.001, respectively), we demonstrated that overall CVH score (β = −0.262; SE = 0.077; p = 0.001), as well as BMI (β = −1.305; SE = 0.194; p < 0.001) and blood pressure CVH metrics (β = −0.607; SE = 0.206; p = 0.004) were significantly associated with EAT thickness but not with IMT. Conclusions: Our study is important as it demonstrated for the first time that CVH is associated with EAT thickness. Interestingly, this relationship seems to be dependent on BMI and blood pressure rather than on the other CVH metrics. However, outcome-driven studies are required to confirm these findings.
Liver Transplantation for Non-HCC Malignancies: Cholangiocarcinoma, Neuroendocrine Tumors, HEHE, and Colorectal Metastases
Zamora‐Valdés, Daniel , Heimbach, Julie K.

Mayo Clinic

Liver Transplantation | May 13, 2018 | Volume: No volume available | Issue: No issue available | Pages: 25-47

10.1142/9789813234680_0002 Get It